TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01624246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil/Avibactam (CXL)
Description: IV infusion of CXL (combination of ceftaroline fosamil \[600 mg\] plus avibactam \[600 mg\]) infused over 60 (± 5) minutes.
Study: NCT02472184

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Office hysteroscopy
Description: Office hysteroscopy is a procedure performed in the office in which a flexible hysteroscope is inserted into the uterine cavity. The patient is positioned in a dorsal lithotomy position and teh cervix is visualized with a speculum. Normal saline is used to distend the cavity, and the hysteroscope is used to visualize any abnormalities within the cavity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Office hysteroscopy
Description: Office hysteroscopy is a procedure performed in the office in which a flexible hysteroscope is inserted into the uterine cavity. The patient is positioned in a dorsal lithotomy position and teh cervix is visualized with a speculum. Normal saline is used to distend the cavity, and the hysteroscope is used to visualize any abnormalities within the cavity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial biopsy
Description: An endometrial biopsy is a procedure in which a pipelle instrument is inserted into the uterine cavity and suction from the pipelle is used to obtain endometrial tissue. This is performed with the patient in the dorsal lithotomy position and a speculum is used to visualize the cervix.
Study: NCT03772288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Intravenous infusion.
Study: NCT04568824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GraphoLearn reading intervention
Description: This is an Edtech reading intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vektor math control intervention
Description: This is an Edtech math/cognition intervention
Study: NCT00726401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COLD-fX
Description: 200mg BID for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg BID for 4 weeks
Study: NCT03041129

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Description: 6 hours OGTT

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Description: 6 hours OGTT
Study: NCT03041129

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Description: 6 hours OGTT
Study: NCT04143269

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive transcutaneous vagus nerve stimulation
Description: Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vagus nerve stimulation
Description: Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.~The sham device produces a slight vibrating sensation, but do not provide any vagal nerve activation
Study: NCT02472184

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial biopsy
Description: An endometrial biopsy is a procedure in which a pipelle instrument is inserted into the uterine cavity and suction from the pipelle is used to obtain endometrial tissue. This is performed with the patient in the dorsal lithotomy position and a speculum is used to visualize the cervix.
Study: NCT00721305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Lovastatin 40 mg daily (2 tablets of 20 mg each, p.o.), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered daily (2 tablets which will look externally identical to intervention: wrapped in the same way, with the same size, shape and color), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
Study: NCT04519723

Intervention type: DEVICE
Group type: OTHER
Intervention: Assess the safety and efficacy of light-laser therapy using the Harmony XL and Dye-VL (500-600nm), Q-Switched 1064nm, Er:YAG 2940nm modules in combination .
Study: NCT01819519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: The patient will told if previously infected or seronegative and what is the risk of the becoming infected. The research assistant will deliver a 5-10 minutes educational intervention, which will consist of a CMV video and some Q\&A.
Study: NCT02743247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Study: NCT03972722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-010
Description: Patients will be given 240mg GLS-010 every treatment.
Study: NCT02000141

Intervention type: PROCEDURE
Intervention: Endoscopic Mucosal Resection
Study: NCT01743638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR-Guided Laser Ablation
Study: NCT03529877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allo-APZ2-EB
Description: intravenous infusion of allo-APZ2-EB
Study: NCT03728946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Addition of 15mL of liposomal bupivacaine to 15mL of standard nerve block anesthetic solution containing 0.5% bupivacaine and 4mg of decadron
Study: NCT05565963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise intervention
Description: The experimental group received VR exercise sessions for 75-90 minutes, twice a week for a duration of 12 weeks.
Study: NCT02561936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Oral Tablet
Description: Rilpivirine formulated as 25 mg oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Oral Tablet
Description: Rilpivirine formulated as 25 mg oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Oral Tablet
Description: Rilpivirine formulated as 25 mg oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Oral Tablet
Description: Rilpivirine formulated as 25 mg oral tablet.
Study: NCT03041129

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Description: 6 hours OGTT

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI of liver
Description: MRI of the liver and use of DIXON method

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI of liver
Description: MRI of the liver and use of DIXON method

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI of liver
Description: MRI of the liver and use of DIXON method
Study: NCT00592475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study: NCT00080782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Oral celecoxib twice daily in the absence of disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: By vein (IV) over 30 minutes on days 1, 8, 15, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: By vein (IV) over 30 minutes on days 1, 8, 15, and 22

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Strontium chloride Sr 89
Description: IV on day 1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Strontium chloride Sr 89
Description: IV on day 1
Study: NCT01743482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study: NCT03455699

Intervention type: DEVICE
Intervention: VenaSeal SCS
Description: Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.

Intervention type: DEVICE
Intervention: ClosureFast Radiofrequency Ablation (RFA)
Description: Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.

Intervention type: DEVICE
Intervention: Roll-In (VenaSeal SCS)
Description: Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
Study: NCT03544073

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution for Injection
Description: Placebo arm will receive a saline injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Treatment arm will receive a Leuprolide injection
Study: NCT02814149

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Type 1 implant placement
Description: Implant is placed immediately following tooth extraction in one surgical procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Type 3 implant placement
Description: Implant is placed in the site which is left to heal for 3 months following tooth extraction
Study: NCT01691469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Description: Montelukast Sodium Oral Granules 4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast sodium
Description: Montelukast Sodium Oral Granules 4mg
Study: NCT03461133

Intervention type: OTHER
Intervention: Intervention
Description: The emergency notification system is linked to a paging system to the surgeon in charge and to the Hospital Medical Emergency Team. Depending on individual Multiparameter Early Warning Score communication protocols are activated.
Study: NCT05922748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imaging
Description: Brain activation is demonstrated by measuring signal changes in brain regions. Activations will be determined by comparison between conditions and in relation to periods of rest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: imaging
Description: Brain activation is demonstrated by measuring signal changes in brain regions. Activations will be determined by comparison between conditions and in relation to periods of rest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: imaging
Description: Brain activation is demonstrated by measuring signal changes in brain regions. Activations will be determined by comparison between conditions and in relation to periods of rest
Study: NCT03041129

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI of liver
Description: MRI of the liver and use of DIXON method
Study: NCT03310762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alma Sana Bracelet
Description: Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
Study: NCT05922748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evoked Potentials
Description: EEG signals, referenced to the right mastoid, were digitised at 125 Hz with an elliptical low-pass input filter at 49 Hz

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evoked Potentials
Description: EEG signals, referenced to the right mastoid, were digitised at 125 Hz with an elliptical low-pass input filter at 49 Hz
Study: NCT03310762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple Silicon Bracelet
Description: Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
Study: NCT04329624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Levosimendan 2.5 mg/ml injection contains levosimendan 2.5 mg, povidone 10.0 mg, citric acid, anhydrous 2.0 mg and ethanol, anhydrous to 1.0 mL. Levosimendan injection is a clear, yellow to orange solution. Immediately after skin incision patients allocated to the verum group will receive a dose of 12.5 mg in 500 mL of levosimendan.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2.5 mg/ml injection contains riboflavine sodium phosphate 0.4 mg, dehydrated alcohol 100 mg and water for injection to 1 mL.~Immediately after skin incision patients allocated to the placebo group will receive 500 mL of 5% Glucose.
Study: NCT01941966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine, PO, 825mg/m2, on days: 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 36, 37, 38, 39 and 40 of radiotherapy period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycins
Description: 15 mg/m2, IV, bolus, single dose on day 1 of radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Dose: 50,4-54 Gy 28 to 30 fractions during 5 to 6 weeks
Study: NCT05922748

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evoked Potentials
Description: EEG signals, referenced to the right mastoid, were digitised at 125 Hz with an elliptical low-pass input filter at 49 Hz

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEG
Description: MEG signals reflect changes in magnetic field evoked by changes in neuronal activity
Study: NCT02610101

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional SCD Diet
Description: Traditional SCD includes removal of all processed foods as well as all grains, sweetners except for honey and all diary except for yogurt fermented for over 24hrs and some hard cheeses

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified SCD Diet
Description: Food components of the traditional SCD with the addition of rice and oats.
Study: NCT05922748

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MEG
Description: MEG signals reflect changes in magnetic field evoked by changes in neuronal activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MEG
Description: MEG signals reflect changes in magnetic field evoked by changes in neuronal activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural tests
Description: Behavioural tests will be evaluated.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural tests
Description: Behavioural tests will be evaluated.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural tests
Description: Behavioural tests will be evaluated.
Study: NCT02610101

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole foods diet
Description: A whole foods diet with removal of processed foods. Removal of corn, wheat, sugar and milk are also apart of this dietary regime.
Study: NCT03287271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6063
Description: Phase 1:~* First 3 patient cohort: VS-6063 200 mg PO twice daily~* IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily,~Phase 2:~VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Phase 1:~* First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~* IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~Phase 2:~Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity.
Study: NCT03145298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Cardiosphere-Derived Stem Cells
Description: Human Allogeneic Cardiosphere-Derived Cells is a biologic product consisting largely of cells grown from donated human heart muscle tissue

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For use in Phase 1b - Double-blind randomized control portion of the study
Study: NCT00110019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT02455635

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: office hystroscopy
Description: Office hysteroscopythrough vaginoscopic approach was done in gynecology out-patient clinic using a 4 mm endoscopic sheath \& 30 ᵒ endoscopic camera with saline distension medium using 90-100 mmHg pressure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: office hystroscopy
Description: Office hysteroscopythrough vaginoscopic approach was done in gynecology out-patient clinic using a 4 mm endoscopic sheath \& 30 ᵒ endoscopic camera with saline distension medium using 90-100 mmHg pressure
Study: NCT00374738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery for Trauma (GIFT)
Description: Guided Imagery for Trauma (GIFT) - music and voice narration over a 12-week intervention. The control intervention included a relaxing music audio (the same music used in the guided imagery audio but without the narrative voiceover), PDA to log audio use, orientation and weekly phone consults, but did not have access to the patient advocate or to the guided imagery instructions provided on the GIFT audio.
Study: NCT01897467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wii Fit
Description: Exercises to be done on the Wii Fit include: warrior pose, half-moon pose, lunges, side lunges, balance bubble, ski slalom, soccer heading, and table tilt.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait-List Control
Description: Participants maintain currently physical activity and diet habits for 12 weeks. They have the option to participate in the intervention at the end of the 12-week period, but it is not mandatory.
Study: NCT03287271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Phase 1:~* First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~* IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity.
Study: NCT03337919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Up to 8 cycles of nivolumab
Study: NCT02275884

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dark chocolate (85% cocoa)

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Dark chocolate (85% cocoa)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White chocolate (0% cocoa)

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: White chocolate (0% cocoa)
Study: NCT00846183

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local injury
Description: In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed
Study: NCT03538171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entinostat
Description: Entinostat will be repeatedly administered PO on days 1, 8, 15 and 22 of each treatment cycle. Exemestane PO once daily on day 1-28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane PO once daily on day 1-28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exemestane
Description: Exemestane PO once daily on day 1-28.
Study: NCT04339842

Intervention type: OTHER
Intervention: Assessment of Dietary Changes in Adults in the Quarantine
Description: The online survey will help to collect demographic data from the volunteers. Personal information and contact details, such as email, will not be asked. The survey will include questions about any increase or decrease in the consumption of main meals, snacks and fluid intake. If the participants of the study have observed changes in their dietary pattern since the beginning of the quarantine, details of these changes, such as an increase in the amount of main meal consumption, will be questioned.
Study: NCT00545129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg IV
Description: Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen.
Study: NCT01110395

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MR Spectroscopy
Description: MR spectroscopy of myocardial
Study: NCT03947814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimodivir
Description: Participants will receive single oral dose of 600 mg pimodivir as 2\*300 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimodivir
Description: Participants will receive single oral dose of 600 mg pimodivir as 2\*300 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimodivir
Description: Participants will receive single oral dose of 600 mg pimodivir as 2\*300 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimodivir
Description: Participants will receive single oral dose of 600 mg pimodivir as 2\*300 mg tablets.
Study: NCT04044755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myopia prediction algorithm
Description: Candidate predictors mainly includes age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.